PABPC5

Summary

PABPC5 (poly(A) binding protein cytoplasmic 5, HGNC:13629) is a protein-coding gene on chromosome Xq21.31, encoding Polyadenylate-binding protein 5 (Q96DU9). Binds the poly(A) tail of mRNA.

This gene encodes a protein that binds to the polyA tail found at the 3’ end of most eukaryotic mRNAs. It is thought to play a role in the regulation of mRNA metabolic processes in the cytoplasm. This gene is located in a gene-poor region within the X-specific 13d-sY43 subinterval of the chromosome Xq21.3/Yp11.2 homology block. It is located close to translocation breakpoints associated with premature ovarian failure, and is therefore a potential candidate gene for this disorder.

Source: NCBI Gene 140886 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Tourette syndrome (Limited, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 59 total
• MANE Select transcript: NM_080832

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13629
Approved symbol	PABPC5
Name	poly(A) binding protein cytoplasmic 5
Location	Xq21.31
Locus type	gene with protein product
Status	Approved
Aliases	PABP5
Ensembl gene	ENSG00000174740
Ensembl biotype	protein_coding
OMIM	300407
Entrez	140886

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000312600, ENST00000373105

RefSeq mRNA: 1 — MANE Select: NM_080832 NM_080832

CCDS: CCDS14460

Canonical transcript exons

ENST00000312600 — 2 exons

Exon	Start	End
ENSE00001203542	91434839	91434894
ENSE00001203546	91435435	91438584

Expression profiles

Bgee: expression breadth ubiquitous, 157 present calls, max score 80.85.

FANTOM5 (CAGE): breadth broad, TPM avg 1.9780 / max 28.6649, expressed in 757 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
196885	1.0201	566
196884	0.6828	390
196883	0.2751	166

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	80.85	gold quality
calcaneal tendon	UBERON:0003701	77.16	gold quality
right adrenal gland cortex	UBERON:0035827	74.10	gold quality
right adrenal gland	UBERON:0001233	73.79	gold quality
left adrenal gland	UBERON:0001234	73.41	gold quality
left adrenal gland cortex	UBERON:0035825	73.18	gold quality
smooth muscle tissue	UBERON:0001135	72.95	gold quality
adrenal gland	UBERON:0002369	72.62	gold quality
ventricular zone	UBERON:0003053	72.16	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	72.00	silver quality
left ovary	UBERON:0002119	71.67	gold quality
adrenal cortex	UBERON:0001235	71.07	gold quality
islet of Langerhans	UBERON:0000006	70.29	gold quality
right ovary	UBERON:0002118	70.01	gold quality
descending thoracic aorta	UBERON:0002345	69.99	gold quality
popliteal artery	UBERON:0002250	69.85	gold quality
tibial artery	UBERON:0007610	69.84	gold quality
ganglionic eminence	UBERON:0004023	69.31	gold quality
ovary	UBERON:0000992	69.06	gold quality
aorta	UBERON:0000947	68.85	gold quality
left coronary artery	UBERON:0001626	68.27	gold quality
thoracic aorta	UBERON:0001515	67.91	gold quality
ascending aorta	UBERON:0001496	67.61	gold quality
right coronary artery	UBERON:0001625	67.32	gold quality
lower esophagus muscularis layer	UBERON:0035833	66.95	gold quality
lower esophagus	UBERON:0013473	66.87	gold quality
body of uterus	UBERON:0009853	66.76	gold quality
mucosa of stomach	UBERON:0001199	66.71	gold quality
coronary artery	UBERON:0001621	66.68	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	66.61	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.02

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

119 targeting PABPC5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-3682-5P	99.93	67.97	1163
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-1305	99.91	71.43	3443

Literature-anchored findings (GeneRIF, showing 1)

• although function of PABPN1 may be compensated by nuclear translocation of PABP4 and perhaps by increase the cytoplasmic abundance of PABP5, these were not sufficient to prevent apoptosis of cells. PABPN1 may have an anti apoptotic role in mammalian cells (PMID:23300856)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Pabpc5	ENSMUSG00000034732
rattus_norvegicus	Pabpc5	ENSRNOG00000003354

Paralogs (24): ELAVL1 (ENSG00000066044), PABPC1 (ENSG00000070756), RBMS2 (ENSG00000076067), PABPC4 (ENSG00000090621), PABPC1L (ENSG00000101104), ELAVL2 (ENSG00000107105), RBM24 (ENSG00000112183), TARDBP (ENSG00000120948), HNRNPR (ENSG00000125944), RBM38 (ENSG00000132819), SYNCRIP (ENSG00000135316), SF3B4 (ENSG00000143368), RBMS3 (ENSG00000144642), PABPC3 (ENSG00000151846), RBMS1 (ENSG00000153250), RBM45 (ENSG00000155636), ELAVL4 (ENSG00000162374), PUF60 (ENSG00000179950), PABPC1L2B (ENSG00000184388), PABPC1L2A (ENSG00000186288), RBM34 (ENSG00000188739), ELAVL3 (ENSG00000196361), RBM14 (ENSG00000239306), PABPC4L (ENSG00000254535)

Protein

Protein identifiers

Polyadenylate-binding protein 5 — Q96DU9 (reviewed: Q96DU9)

All UniProt accessions (2): Q96DU9, Q5JQF3

UniProt curated annotations — full annotation on UniProt →

Function. Binds the poly(A) tail of mRNA. May be involved in cytoplasmic regulatory processes of mRNA metabolism. Can probably bind to cytoplasmic RNA sequences other than poly(A) in vivo.

Subcellular location. Cytoplasm Mitochondrion matrix.

Tissue specificity. Expressed in fetal brain and in a range of adult tissues.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96DU9-1	1	yes
Q96DU9-2	2

RefSeq proteins (1): NP_543022* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR003954	RRM_euk-type	Domain
IPR006515	PABP_1234	Family
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR034364	PABP_RRM1	Domain
IPR035979	RBD_domain_sf	Homologous_superfamily
IPR045305	RRM2_I_PABPs	Domain

Pfam: PF00076

UniProt features (7 total): domain 4, chain 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96DU9-F1	91.44	0.79

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 82 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, GCANCTGNY_MYOD_Q6, AP4_Q6, TAL1ALPHAE47_01, CAGCTG_AP4_Q5, TGCTGAY_UNKNOWN, GOCC_CYTOPLASMIC_STRESS_GRANULE, GOCC_MITOCHONDRIAL_MATRIX, GOCC_RIBONUCLEOPROTEIN_GRANULE, E2A_Q2, GOCC_RIBONUCLEOPROTEIN_COMPLEX, GOMF_POLY_A_BINDING, GOMF_POLY_PYRIMIDINE_TRACT_BINDING, GOMF_MRNA_BINDING, GOMF_SINGLE_STRANDED_RNA_BINDING

GO Biological Process (0):

GO Molecular Function (6): mRNA 3’-UTR binding (GO:0003730), poly(A) binding (GO:0008143), poly(U) RNA binding (GO:0008266), nucleic acid binding (GO:0003676), RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (7): nucleus (GO:0005634), mitochondrial matrix (GO:0005759), cytosol (GO:0005829), cytoplasmic stress granule (GO:0010494), ribonucleoprotein complex (GO:1990904), cytoplasm (GO:0005737), mitochondrion (GO:0005739)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
intracellular membrane-bounded organelle	2
cytoplasm	2
cellular anatomical structure	2
mRNA binding	1
poly-purine tract binding	1
poly-pyrimidine tract binding	1
nucleic acid binding	1
mitochondrion	1
intracellular organelle lumen	1
cytoplasmic ribonucleoprotein granule	1
protein-containing complex	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1474 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PABPC5	TGIF2LX	Q8IUE1	943
PABPC5	TGIF2LY	Q8IUE0	930
PABPC5	PABPN1	Q86U42	875
PABPC5	EIF4G1	Q04637	789
PABPC5	TGIF2	Q9GZN2	784
PABPC5	PCDH11X	Q9BZA7	762
PABPC5	EIF4E	P06730	680
PABPC5	TGFBI	Q15582	635
PABPC5	TNRC6A	Q8NDV7	598
PABPC5	EIF4A1	P04765	595
PABPC5	EIF4A2	Q14240	594
PABPC5	PAIP2	Q9BPZ3	541
PABPC5	PAN2	Q504Q3	531
PABPC5	ATXN2	Q99700	485
PABPC5	A0A087WUC5	A0A087WUC5	438

IntAct

23 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
PABPC5	PAIP2	psi-mi:“MI:0915”(physical association)	0.670
ESR1	TRIM24	psi-mi:“MI:0914”(association)	0.640
LIN28B	ELAVL2	psi-mi:“MI:0914”(association)	0.530
RFX3	IGSF8	psi-mi:“MI:0914”(association)	0.350
ESR2		psi-mi:“MI:0914”(association)	0.350
EPHB6	PGRMC1	psi-mi:“MI:0914”(association)	0.350
PABPC5	APOBEC3DE	psi-mi:“MI:0914”(association)	0.350
ZSCAN21	IPO8	psi-mi:“MI:0914”(association)	0.350
PABPC5	IGF2BP3	psi-mi:“MI:0914”(association)	0.350
FTL		psi-mi:“MI:0914”(association)	0.350
LIN28A	GTPBP10	psi-mi:“MI:0914”(association)	0.350
PRR3	POLRMT	psi-mi:“MI:0914”(association)	0.350
RPF1	CAPG	psi-mi:“MI:0914”(association)	0.350
TUSC3	STK17B	psi-mi:“MI:0914”(association)	0.350
YBX2	GTPBP10	psi-mi:“MI:0914”(association)	0.350
PABPC5	PAIP2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (153): PABPC5 (Affinity Capture-MS), PABPC5 (Affinity Capture-MS), PABPC5 (Affinity Capture-MS), PABPC5 (Affinity Capture-MS), PABPC5 (Affinity Capture-MS), PABPC5 (Affinity Capture-MS), PABPC5 (Affinity Capture-MS), PABPC5 (Two-hybrid), PABPC5 (Affinity Capture-MS), PABPC5 (Affinity Capture-MS), PABPC5 (Affinity Capture-MS), PABPC5 (Affinity Capture-MS), PABPC5 (Affinity Capture-MS), HERC1 (Affinity Capture-MS), PTBP3 (Affinity Capture-MS)

ESM2 similar proteins: A2A5N3, A3LXL0, A5DM21, F1QB54, F4HT49, G5EFS2, O04319, O22173, O64380, O74968, P04147, P0CB38, P11940, P20965, P21187, P29341, P31209, P42731, P49960, P60047, P60048, P60049, P60050, P61286, P70318, Q05196, Q08BH5, Q0P4R6, Q13310, Q22708, Q4VXU2, Q503H1, Q54BM2, Q5JQF8, Q5R8F7, Q6BI95, Q6DCB7, Q6DEY7, Q6FKG4, Q6GR16

Diamond homologs: A0A0D1DWZ5, A0JM51, A1CRM1, A1D4K4, A2A5N3, A2Q848, A3LXL0, A4IIM2, A4QUF0, A5DW14, F4HT49, O04319, O14102, O22173, O57406, O64380, O95319, O97018, P04147, P0CB38, P0CP46, P0CP47, P20965, P21187, P28659, P29558, P31209, P32588, P39697, P42731, P60047, P60048, P60049, P60050, Q08E07, Q09442, Q0CR95, Q0U1G2, Q13310, Q15427

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

59 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	31
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

190 predictions. Top by Δscore:

Variant	Effect	Δscore
X:91434906:G:GG	donor_gain	0.9600
X:91434905:A:AG	donor_gain	0.9500
X:91434901:ACCC:A	donor_gain	0.8800
X:91434895:G:GG	donor_gain	0.8700
X:91434892:TCGG:T	donor_loss	0.8600
X:91434893:CGGT:C	donor_loss	0.8600
X:91434894:GG:G	donor_loss	0.8600
X:91434896:TCCG:T	donor_loss	0.8600
X:91434897:CCGT:C	donor_loss	0.8600
X:91434898:CGTA:C	donor_loss	0.8600
X:91434899:G:C	donor_loss	0.8500
X:91435551:G:C	acceptor_gain	0.8200
X:91434868:GCTGC:G	donor_gain	0.7700
X:91435549:A:C	acceptor_gain	0.7600
X:91435522:TAGAG:T	acceptor_gain	0.7200
X:91435523:AGAGA:A	acceptor_gain	0.7200
X:91435526:G:GT	acceptor_gain	0.7200
X:91434923:C:G	donor_gain	0.7100
X:91435417:TGAAC:T	acceptor_gain	0.6800
X:91434909:G:A	donor_gain	0.6300
X:91434921:ATCTG:A	donor_gain	0.6300
X:91435431:TCAGC:T	acceptor_gain	0.6300
X:91435432:CAGCC:C	acceptor_gain	0.6300
X:91434922:TCTGG:T	donor_gain	0.6100
X:91436037:A:AG	acceptor_gain	0.6100
X:91436038:G:GG	acceptor_gain	0.6100
X:91434911:C:T	donor_gain	0.5900
X:91435521:TTAGA:T	acceptor_gain	0.5900
X:91435418:GAAC:G	acceptor_gain	0.5800
X:91435428:TTC:T	acceptor_gain	0.5700

AlphaMissense

2524 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:91436026:T:A	V150D	0.995
X:91436304:T:C	F243L	0.995
X:91436306:T:A	F243L	0.995
X:91436306:T:G	F243L	0.995
X:91436031:T:C	F152L	0.993
X:91436033:T:A	F152L	0.993
X:91436033:T:G	F152L	0.993
X:91436169:T:C	F198L	0.993
X:91436171:C:A	F198L	0.993
X:91436171:C:G	F198L	0.993
X:91436302:G:A	G242E	0.993
X:91436185:T:A	V203D	0.992
X:91436340:G:C	A255P	0.992
X:91435651:T:C	L25S	0.991
X:91435773:T:C	F66L	0.991
X:91435775:C:A	F66L	0.991
X:91435775:C:G	F66L	0.991
X:91435966:G:T	G130V	0.991
X:91436115:T:C	F180L	0.991
X:91436117:C:A	F180L	0.991
X:91436117:C:G	F180L	0.991
X:91436221:T:C	L215P	0.990
X:91436541:T:C	F322L	0.990
X:91436543:T:A	F322L	0.990
X:91436543:T:G	F322L	0.990
X:91435762:G:A	G62E	0.989
X:91435768:T:A	V64D	0.989
X:91436020:C:A	A148D	0.989
X:91435774:T:C	F66S	0.988
X:91436032:T:C	F152S	0.988

dbSNP variants (sampled 300 via entrez): RS1000710024 (X:91438203 T>C), RS1000783639 (X:91437686 CTTG>C), RS1001725745 (X:91433911 T>A), RS1002819075 (X:91435358 G>A), RS1003391732 (X:91433401 CAA>C), RS1005743233 (X:91437792 C>A), RS1006047727 (X:91435278 C>A), RS1006078789 (X:91434906 G>T), RS1008589667 (X:91438261 T>C), RS1008863633 (X:91433032 C>A,T), RS1009756211 (X:91437584 AATTT>A), RS1010347833 (X:91434753 T>C), RS1011806057 (X:91434381 G>A), RS1012489449 (X:91439030 T>A), RS1013860684 (X:91438697 A>G)

Disease associations

OMIM: gene MIM:300407 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Tourette syndrome	Limited	Unknown

Mondo (1): Tourette syndrome (MONDO:0007661)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001613_10	Antineutrophil cytoplasmic antibody-associated vasculitis	4.000000e-08
GCST010298_3	Metopic nonsyndromic craniosynostosis	6.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0008511	metopic craniosynostosis

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	6
Benzo(a)pyrene	affects methylation, increases expression	2
methylmercuric chloride	decreases expression	1
trichostatin A	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol Z	increases expression	1
Sunitinib	decreases expression	1
Vorinostat	increases expression	1
Panobinostat	increases expression	1
Phenylmercuric Acetate	affects cotreatment, increases expression	1
Okadaic Acid	decreases expression	1
Permethrin	increases expression	1

Clinical trials (associated diseases)

183 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	PHASE4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	PHASE4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	PHASE4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	PHASE4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	PHASE4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00004376	PHASE3	COMPLETED	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
NCT00206323	PHASE3	COMPLETED	A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT00206336	PHASE3	COMPLETED	An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
NCT00478842	PHASE3	COMPLETED	Pallidal Stimulation and Gilles de la Tourette Syndrome
NCT00681863	PHASE3	TERMINATED	Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
NCT01501695	PHASE3	COMPLETED	Phase III Study of 5LGr to Treat Tic Disorder
NCT03087201	PHASE3	COMPLETED	CANNAbinoids in the Treatment of TICS (CANNA-TICS)
NCT03487783	PHASE3	COMPLETED	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette’s Syndrome
NCT03567291	PHASE3	TERMINATED	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03571256	PHASE3	COMPLETED	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT06021522	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette’s Disorder
NCT00004393	PHASE2	COMPLETED	Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
NCT00004652	PHASE2	COMPLETED	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
NCT00231985	PHASE2	COMPLETED	Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
NCT00311909	PHASE2	COMPLETED	Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00529308	PHASE2	COMPLETED	Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette’s Syndrome
NCT00558467	PHASE2	COMPLETED	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT01043549	PHASE2	TERMINATED	Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
NCT01133353	PHASE2	WITHDRAWN	A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette’s Syndrome
NCT01475383	PHASE2	WITHDRAWN	Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette’s Syndrome
NCT01647269	PHASE2	COMPLETED	A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
NCT01904773	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder
NCT02102698	PHASE2	COMPLETED	Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years
NCT02217007	PHASE2	WITHDRAWN	A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02247206	PHASE2	COMPLETED	VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02581865	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02619084	PHASE2	COMPLETED	Subthalamic Stimulation in Tourette’s Syndrome
NCT02679079	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02879578	PHASE2	COMPLETED	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT03066193	PHASE2	COMPLETED	Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03247244	PHASE2	TERMINATED	Safety and Efficacy of Cannabis in Tourette Syndrome
NCT03325010	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038	PHASE2	COMPLETED	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome